Tango Therapeutics (NASDAQ: TNGX)
Tango Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Tango Therapeutics Company Info
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.
News & Analysis
Why Shares of Tango Therapeutics Are Dropping Monday
Another company's buyout helped drive up the price last week. This week, investors started out by selling the stock.
Why Shares of Tango Therapeutics Climbed This Week
The company got the go-ahead last week from the FDA for a drug's IND.
Up 126% in 3 Days, Is Tango Therapeutics a Buy Right Now?
Remember that past performance doesn't predict future returns.
Why Shares of Tango Therapeutics Skyrocketed This Week
The company had several announcements as part of its second-quarter earnings report.
Why Tango Therapeutics Shares Rose 39.7% This Week
The clinical-stage biotech company has two candidates in its drug pipeline.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.